CDXS.NASDAQCodexis, INC

10-K: Codexis, Inc. Reports Fiscal Year 2024 Results, Focuses on Pharma Biocatalysis and RNAi Manufacturing

Sentiment:

Annual Results

📋All filings for Codexis, INC
🔒Login to Follow

Codexis, Inc. announces its 2024 financial results, highlighting its strategic focus on pharma biocatalysis and the ECO Synthesis manufacturing platform for RNAi therapeutics.

Capital raiseDuring the year ended December 31, 2024, 10,440,000 shares of the company's common stock were issued and sold pursuant to the Cantor Sales Agreement for gross proceeds of $31.3 million.As of December 31, 2024, $43.7 million remained available for sale under the Cantor Sales Agreement.
Worse than expectedThe company reported a net loss of $65.3 million, which is worse than expected.Product revenue decreased by 14% compared to 2023, primarily due to one-time revenue recognition in the prior year.Research and development revenue decreased by 17% compared to 2023, primarily due to lower revenue from Nestl and Pfizer.

Summary

  • Codexis, Inc. reported a net loss of $65.3 million for the year ended December 31, 2024.
  • The company is focusing on two key areas: pharma biocatalysis and the ECO Synthesis manufacturing platform.
  • In July 2023, Codexis discontinued investment in certain development programs, primarily in its novel biotherapeutics business segment.
  • The company divested certain biotherapeutics and non-core life science assets during 2024.
  • Codexis is leveraging its CodeEvolver technology platform to develop enzymes for RNAi therapeutics.
  • In November 2024, Codexis presented data demonstrating the successful enzymatic synthesis of an siRNA therapeutic asset.
  • The ECO Synthesis Innovation Lab was completed at the end of 2024, enabling gram-scale siRNA synthesis for pre-clinical testing.
  • Codexis expects to manufacture GLP-grade siRNA in 2025 and partner with a CDMO for GMP-grade siRNA production.
  • The company is monetizing non-core assets and leveraging channel partners to drive penetration of other developed enzymes.
  • As of December 31, 2024, Codexis owned or controlled approximately 1,760 active issued patents and pending patent applications.
  • Four customers accounted for approximately 51% of the company's total revenues for the year ended December 31, 2024.
  • The company borrowed $30.0 million from Innovatus Life Sciences Lending Fund I, LP in February 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is focusing on promising areas and has achieved some technical milestones, it is still facing financial challenges and risks.

Positives

  • Codexis is focusing on high-potential areas like pharma biocatalysis and RNAi manufacturing.
  • The ECO Synthesis platform offers advantages over traditional chemical synthesis for RNAi therapeutics.
  • The company has a proven history of engineering complex enzymes for large pharmaceutical companies.
  • Codexis is expanding its pipeline of enzymes for clinical-stage manufacturing.
  • The company is monetizing non-core assets to generate revenue.
  • Codexis has a strong intellectual property portfolio.
  • The company has partnerships with major pharmaceutical companies like Merck and Pfizer.

Negatives

  • Codexis has a history of net losses and may not achieve or maintain profitability.
  • The company is dependent on a limited number of customers.
  • The demand for the company's products depends in part on its customers' research and development and the clinical and market success of their products.
  • The timing of customer orders and related product revenue recognition is unpredictable and may cause the company's operating results to vary significantly from quarter to quarter.
  • The company is dependent on a limited number of third-party contract manufacturers for large scale production of substantially all of its enzymes.

Risks

  • The ability of Codexis' customers to advance product candidates utilizing its products to clinical trials and to ultimately receive regulatory approvals is highly uncertain.
  • The company may need additional capital in the future in order to expand its business.
  • The company may not be able to comply with the terms of its five-year term loan and security agreement with Innovatus Life Sciences Lending Fund I, LP.
  • Third parties may claim that the company is infringing, violating or misappropriating their intellectual property rights, which may subject the company to costly and time-consuming litigation.
  • Market and economic conditions may negatively impact the company's business, financial condition, and share price.
  • Business interruptions resulting from political events, disasters or other disturbances could delay the company in the process of developing its products and could disrupt its sales.

Future Outlook

Codexis expects to manufacture GLP-grade siRNA for customers in its Innovation Lab under development services contracts model in 2025 and anticipates entering a partnership with a large-scale CDMO to synthesize GMP-grade siRNA drug substance for its customers.

Industry Context

The document highlights the growing demand for RNAi therapeutics and the limitations of current chemical-based manufacturing methods, positioning Codexis' ECO Synthesis platform as a potential solution for scalable and sustainable RNAi manufacturing.

Comparison to Industry Standards

  • The current industry standard for manufacturing RNAi therapeutics is solid-phase oligonucleotide synthesis (SPOS) utilizing phosphoramidite chemistry, which faces limitations in scalability and cost.
  • Competitors in the RNA manufacturing space include CDMOs like Agilent Technologies, which have invested heavily in phosphoramidite chemistry, and early-stage companies pursuing fully enzymatic approaches like EnPlusOne Biosciences.
  • Codexis' ECO Synthesis platform aims to address the limitations of SPOS by offering a more scalable, cost-effective, and environmentally friendly alternative.
  • The company's collaboration with Bachem, a leading CDMO in oligonucleotide manufacturing, provides external validation of the superior performance of its engineered dsRNA ligases.

Stakeholder Impact

  • Shareholders: The company's financial performance and strategic direction will impact shareholder value.
  • Employees: The company's restructuring and focus on specific areas may affect employee roles and opportunities.
  • Customers: The company's development of new technologies and partnerships will impact the availability and quality of its products and services.
  • Suppliers: The company's reliance on third-party manufacturers will impact its relationships with suppliers.
  • Creditors: The company's debt obligations and financial performance will impact its relationships with creditors.

Next Steps

  • Codexis expects to manufacture GLP-grade siRNA in 2025.
  • The company anticipates entering a partnership with a large-scale CDMO for GMP-grade siRNA production in 2025.
  • Codexis intends to expand its enzymatic tools and process offerings to address the overall market needs for scalable and sustainable RNAi manufacturing.

Key Dates

DateDescription
2002Codexis incorporated in Delaware as a wholly-owned subsidiary of Maxygen, Inc.
March 2002Codexis commenced independent operations.
October 2010Codexis acquired substantially all of the patents and other intellectual property rights associated with Maxygens directed evolution technology.
February 2012Codexis entered into a five-year Sitagliptin Catalyst Supply Agreement with Merck.
May 2019Codexis entered into a Platform Technology Transfer and License Agreement with Novartis.
March 2020Codexis entered into a Strategic Collaboration and License Agreement with Takeda Pharmaceutical Co. Ltd.
June 2020Codexis entered into a Master Collaboration and Research Agreement with Molecular Assemblies, Inc.
March 2022Codexis entered into a Stock Purchase Agreement with seqWell, Inc.
July 2022Codexis and MAI announced that they had entered into a Commercial License and Enzyme Supply Agreement with MAI.
April 2023Takeda discontinued its efforts in adeno-associated virus (AAV) gene therapy, including these development programs.
July 2023Codexis announced that it discontinued investment in certain development programs, primarily in its novel biotherapeutics business segment.
September 2023Codexis entered into a new non-exclusive commercial and manufacturing license agreement with Alphazyme.
December 2023Codexis entered into an acquisition agreement with Nestl.
February 2024Codexis entered into a license agreement with Roche Sequencing Solutions, Inc.
February 13, 2024Codexis entered into the Loan Agreement with Innovatus.
January 28, 2025Maravai LifeSciences, Inc. announced its acquisition of intellectual property and relevant assets from MAI.
January 2025Codexis sold assets that were developed under the seqWell Agreement to seqWell.
February 24, 2025There were 82,837,311 shares of the registrants Common Stock outstanding.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.